	US 11,697,665 B2
	C-mannoside compounds useful for the treatment of urinary tract infections
Michael Joseph Bishop, Research Triangle Park, NC (US); Eugene L. Stewart, Collegeville, PA (US); Katherine Louisa Widdowson, San Diego, CA (US); James Walter Janetka, St. Louis, MO (US); and Laurel Kathryn McGrane, St. Louis, MO (US)
Assigned to Fimbrion Therapeutics, Inc., Saint Louis, MO (US); and GlaxoSmithKline Intellectual Property Development Limited, Middlesex (GB)
Filed by GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, Middlesex (GB); and FIMBRION THERAPEUTICS, INC., St. Louis, MO (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,419.
Application 17/371,419 is a division of application No. 17/063,947, filed on Oct. 6, 2020, granted, now 11,111,262.
Application 17/063,947 is a continuation of application No. PCT/IB2019/055806, filed on Jul. 8, 2019.
Claims priority of provisional application 62/695,993, filed on Jul. 10, 2018.
Claims priority of provisional application 62/755,588, filed on Nov. 5, 2018.
Prior Publication US 2021/0395287 A1, Dec. 23, 2021
Int. Cl. C07H 7/04 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01)

CPC C07H 7/04 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 45/06 (2013.01)]

20 Claims

1. A method of treatment of a FimH-mediated disease in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound which is: